Invasive Mold Infections: Emerging Approaches is an interactive, enduring activity based on a satellite symposium held during IDWeek 2016. This activity is designed to aid specialists in the treatment of invasive mold infections, complete with up-to-date diagnostics and relevant treatment options pertinent to the optimal management within a historically challenging and ever-changing field.
Invasive Mycoses: Emerging Paradigms & Practical Applications is an enduring activity based on content presented at the 2016 MSGERC symposium at ASM Microbe. With content spanning from updates on diagnostics and pharmacologic considerations for therapies to challenges in the management of invasive aspergillosis, invasive mucormycosis, and breakthrough infections, this activity addresses key clinical issues for optimal invasive fungal disease (IFD) management. In addition, we have also included fungus-specific updates from the Microbe meeting in the companion Mycology Minutes™ activity (see link below). We hope you find these activities helpful as you hone and update your strategies for managing these difficult infections.
Release Date:12/31/2016
Expiration Date: 12/30/2017
Estimated Time to Complete the Activity: 1 hr
Media: Text-based presentation, interactive
Release Date:9/25/2016
Expiration Date: 9/24/2017
Estimated Time to Complete the Activity: 2.5 hrs
Media: Text-based presentation, interactive
With increasing numbers of immunocompromised patients at risk for invasive mold infections, it is important to stay abreast of the emerging strategies to manage these particularly difficult infections. Recently, the IDSA issued new invasive aspergillosis guidelines and the experience and literature is growing related to the management of mucormycosis, fusariosis, and other rare molds. This update provides a brief overview over new strategies you can use to break the mold in the management of these devastating infections.
Recently, updated literature and guidelines have been released regarding the management of invasive fungal infections. This information spans from documentation of emerging resistance trends, to diagnostic criteria and options, to updated IDSA guidelines in invasive candidiasis and invasive aspergillosis, to more pharmacologically oriented information regarding newer antifungal therapeutic options. Expert-led discussion should help put these findings/guidelines in context and provide insights into how to translate them in clinical practice. Join this multidisciplinary international panel as they evaluate emerging paradigms in antifungal management as well as their practical application in multidisciplinary case examples.
After completing this activity, the participants should be better able to:
After completing this activity, the participants should be better able to:
This activity is directed to specialists in infectious diseases, hospital medicine, hematology/oncology, pathology, medical microbiology, critical care, pharmacy, and surgery, as well as other healthcare providers responsible for the management of invasive mycoses.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Medical Education; Terranova Medica, LLC; and the Mycoses Study Group Education & Research Consortium.
The University of Nebraska Medical Center, Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Nebraska Medical Center, Center for Continuing Education designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The University of Nebraska Medical Center, Center for Continuing Education designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
As a provider accredited by ACCME, the University of Nebraska Medical Center, Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Faculty are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.
All faculty, planning committee members and others in a position to control continuing medical education content participating in a University of Nebraska Medical Center, Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in these activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.
This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA approved indications.
The following indicates the disclosure declaration information and the nature of those commercial relationships:
PETER G. PAPPAS, MD, FACP
RESEARCH SUPPORT:
Astellas; Gilead Sciences, Inc.; Viamet; Merck & Co, Inc.; Scynexis
ADVISORY COMMITTEE:
Amplyx; Viamet; T2 Biosystems; IMMY; Vical; Scynexis; Matinas
DIMITRIOS P. KONTOYIANNIS, MD, ScD, FACP, FIDSA
CONSULTANT:
Amplyx, Inc.; Cidara Therapeutics, Inc.; F2G, Inc.
ADVISORY COMMITTEE:
Merck & Co, Inc.
SPEAKER:
Astellas
SPEAKER’S BUREAU:
Merck & Co, Inc.
This talk will include discussion of off-label therapies.
SANJAY G. REVANKAR, MD
RESEARCH SUPPORT:
Astellas; Cidara Therapeutics, Inc.; Gilead Sciences, Inc.; Merck & Co, Inc.
This talk will include discussion of off-label therapies.
GEORGE R. THOMPSON, III, MD, FIDSA
RESEARCH SUPPORT:
Merck & Co, Inc.
GRANT SUPPORT/CONSULTANT:
Astellas
GRANT SUPPORT/CLINICAL TRIALS:
Cidara Therapeutics, Inc.; Scynexis
PETER G. PAPPAS, MD, FACP
RESEARCH SUPPORT:
Astellas; Cidara Therapeutics; Gilead Sciences; IMMY; Merck & Co, Inc.; T2 Biosystems; Viamet
ADVISORY COMMITTEE:
Cidara Therapeutics; Matinas BioPharma; T2 Biosystems; Viamet; Vical; Amplyx; Scynexis
ELIZABETH S. DODDS ASHLEY, PharmD
ROYALTIES:
Up to Date
ADVISORY COMMITTEE:
Hospital Association of New York State
SPEAKER’S BUREAU, FACULTY, PEER REVIEWER:
New York State Council of Health System Pharmacists
MAIKEN CAVLING ARENDRUP, PROF, MD, PhD, DMSc
RESEARCH SUPPORT:
Basilea; Gilead; T2 Biosystems
SPEAKER’S BUREAU, FACULTY, PEER REVIEWER:
Astellas; Basilea; Gilead; Merck; Novartis; Pfizer;
T2 Biosystems
THOMAS F. PATTERSON, MD, FACP
ADVISORY COMMITTEE/CONSULTANT:
Amplyx Pharmaceuticals; Astellas; Cidara Therapeutics; Pfizer; Revolution Medicines; Toyama; Viamet; Vical
RESEARCH FUNDING:
Astellas; Revolution Medicines
LOIS COLBURN
UNMC Center for Continuing Education
No conflicts to disclose.
BRENDA C. RAM, CMP, CHCP
UNMC Center for Continuing Education
No conflicts to disclose.
ALISON FREIFELD, MD
University of Nebraska Medical Center
DATA SAFETY MONITORING BOARD:
Astellas; Merck & Co., Inc.
LISA A. TUSHLA, PHD, H(ASCP)
Terranova Medica, LLC
No conflicts to disclose
To receive a CME certificate of participation, participants should:
To participate, you will need access to a computer (either MAC or PC), tablet, or smart phone, with a Chrome (version 22.0.1229.94 or greater) web browser, Firefox (version 3.6 or greater) web browser, Safari (version 6 or greater) web browser, or an Internet Explorer (version 8.0 or greater) web browser, JavaScript enabled, connected to the Internet (high speed connection preferred), and cookies MUST be enabled on your browser.
Terranova Medica, LLC, and UNMC CCE are committed to protecting the privacy of those who choose to participate in activities on funguscme.org. This information below describes our security policies for safeguarding personal information as well as the rationale for collection and use of personal information.
Security/safeguarding personal information
This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.
Collection and use of personal information
To earn CME credits using the website, the UNMC CCE requires submission of certain personally identifiable information. The required items include: first name, last name, degree, and e-mail address. These items are necessary to award and track the credits that participants may earn after completing the program. To obtain credit, learners must complete an evaluation of the CME activity. This information is used in a continuous improvement process to enhance the learning experience of future programs.
Terranova Medica, LLC, and UNMC CCE do not transfer, sell, or share personal information with outside parties. We will not disclose the information unless required in a legal proceeding.
The opinions or views expressed in this continuing education activity are those of the faculty and do not necessarily reflect the opinions or recommendations of the University of Nebraska Medical Center, Center for Continuing Education; the Mycoses Study Group Education & Research Consortium; and Terranova Medica, LLC.
Healthcare professionals and other individuals should review and consider other publications and materials on the subject before relying solely upon the information contained within this educational activity.
There is no charge for this activity.
This activity is supported by independent educational grants from: Astellas; Merck & Co, Inc; Gilead Sciences Europe, Ltd.; and T2 Biosystems.
For further information you may also contact Tom Davis by telephone or fax at 877-276-4523 or by email at tdavis@terranovamedica.com.
Copyright ©2016 UNMC CCE; Terranova Medica, LLC; and MSGERC.
